K20
K20 is a potent and selective KRas G12C inhibitor with an IC50 of 1.16 μM. K20 shows anticancer activity in H358 cells (IC50= 0.78 μM) . K20 decreases the levels of phosphorylated Erk and leads to cancer cell apoptosis. K20 suppresses NCI-H358 tumor growth with a TGI of 41% without causing obvious toxicity[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; ERK; Ras
Type
Reference compound
Related Pathways
Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/k20.html
Solubility
10 mM in DMSO
Smiles
C=C(C(N1CCN([C@@H](C1)C)C2=NC=NC3=C(C(C4=CC(Cl)=CC=C4OC)=C(C=C23)Cl)F)=O)C(F)(F)F
Molecular Formula
C24H20Cl2F4N4O2
Molecular Weight
543.34
References & Citations
[1]Zhao H, et al. Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity. Bioorg Chem. 2022, 121:105652.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
K-Ras
Explore Other Products
Browse additional items from our catalog
NFIC CRISPR All-in-one AAV vector set (with saCas9)(Rat)
Recombinant Saccharophagus degradans Glutamate--cysteine ligase (gshA), partial
CNOT3 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)